{
    "2018-08-27": [
        [
            {
                "time": "2018-08-27",
                "original_text": "复星医药公布半年报，重组人胰岛素产业化项目可用状态日期延至2020年12月，上半年净利润下滑8%，研发费用增长超五成，盈利能力下降。",
                "features": {
                    "keywords": [
                        "复星医药",
                        "半年报",
                        "重组人胰岛素",
                        "研发费用",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-27",
                "original_text": "A股放量大涨：沪指三连阳收复20日线，创业板指暴涨近3%。",
                "features": {
                    "keywords": [
                        "A股",
                        "放量大涨",
                        "沪指",
                        "创业板指"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "整体市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-27",
                "original_text": "港股异动︱复星医药(A股涨停 H股跟涨8.93%)。",
                "features": {
                    "keywords": [
                        "复星医药",
                        "A股涨停",
                        "H股跟涨"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-27",
                "original_text": "医药板块崛起，复星医药、华兰生物等多股涨停。",
                "features": {
                    "keywords": [
                        "医药板块",
                        "复星医药",
                        "涨停"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-28",
                "original_text": "江琦、赵磊：2018H1点评：研发投入大幅增加影响表观利润，创新趋势继续。",
                "features": {
                    "keywords": [
                        "复星医药",
                        "研发投入",
                        "表观利润",
                        "创新趋势"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}